Compare DCGO & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCGO | LPCN |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.0M | 61.8M |
| IPO Year | 2020 | 2011 |
| Metric | DCGO | LPCN |
|---|---|---|
| Price | $0.72 | $10.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $3.33 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 668.5K | 79.9K |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 200.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $616,555,132.00 | $11,198,144.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 492.80 |
| 52 Week Low | $0.66 | $2.52 |
| 52 Week High | $3.18 | $12.37 |
| Indicator | DCGO | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 62.99 |
| Support Level | $0.66 | $2.89 |
| Resistance Level | $0.95 | $10.80 |
| Average True Range (ATR) | 0.07 | 0.82 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 35.87 | 83.18 |
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.